Literature DB >> 26174653

A systematic review of loss of independence in Parkinson's disease.

Angus D Macleod1, J W Kerr Grieve2, Carl E Counsell3.   

Abstract

Functional dependency (needing help with basic ADLs) is an important outcome in Parkinson's disease (PD). "Death or dependency", as opposed to being alive and independent, is a useful dichotomous indicator of poor outcome. We aimed to systematically review the progression to dependency in PD and what factors predicted development of dependency. Comprehensive searches were performed to identify observational studies of dependency in PD with follow-up of at least 3 years. Other forms of parkinsonism and highly selected cohorts were excluded. Descriptive analysis of included studies was performed and outcomes over time were plotted by type of cohort (inception/non-inception). Independent prognostic factors were identified. There were insufficient data for meta-analysis. Of 15,154 unique references identified, 14 studies were included. Most studies were of low quality. There was heterogeneity in definitions of dependency and the measured risk of dependency at similar time-points. Risk of dependency in inception studies was about 10-25 % at 5 years and about 20-50 % at 10 years; and risk of "death or dependency" in the inception studies was about 15-40 % at 5 years and about 35-70 % at ten years. More bradykinesia and older age were associated with more dependency, but there was little evidence for other prognostic factors. Few high-quality data on dependency are available. Heterogeneity in study populations, methodology and outcome reporting made data synthesis difficult. Few prognostic factors have been identified. Further data from representative inception studies are necessary to better understand the progression of dependency in PD.

Entities:  

Keywords:  Activities of daily living; Dependence; Independence; Parkinson’s disease; Systematic review

Mesh:

Year:  2015        PMID: 26174653     DOI: 10.1007/s00415-015-7847-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  33 in total

1.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.

Authors:  Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

2.  Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group.

Authors:  J A Berlin
Journal:  Lancet       Date:  1997-07-19       Impact factor: 79.321

3.  Calculating clinical progression rates in Parkinson's disease: methods matter.

Authors:  Johan Marinus; Jorine F van der Heeden; Jacobus J van Hilten
Journal:  Parkinsonism Relat Disord       Date:  2014-08-20       Impact factor: 4.891

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

5.  Course in Parkinson disease subtypes: A 39-year clinicopathologic study.

Authors:  A H Rajput; A Voll; M L Rajput; C A Robinson; A Rajput
Journal:  Neurology       Date:  2009-07-21       Impact factor: 9.910

6.  Parkinson's disease in Taiwan: an analysis of 215 patients.

Authors:  L G Chia; L H Liu
Journal:  Neuroepidemiology       Date:  1992       Impact factor: 3.282

7.  Systematic evaluation of rating scales for impairment and disability in Parkinson's disease.

Authors:  Claudia Ramaker; Johan Marinus; Anne Margarethe Stiggelbout; Bob Johannes Van Hilten
Journal:  Mov Disord       Date:  2002-09       Impact factor: 10.338

8.  Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease.

Authors:  M M Hoehn
Journal:  Acta Neurol Scand       Date:  1985-02       Impact factor: 3.209

9.  The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.

Authors:  Mariese A Hely; Wayne G J Reid; Michael A Adena; Glenda M Halliday; John G L Morris
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

10.  Using 'dead or dependent' as an outcome measure in clinical trials in Parkinson's disease.

Authors:  David McGhee; Alexander Parker; Shona Fielding; John Zajicek; Carl Counsell
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-05-22       Impact factor: 10.154

View more
  6 in total

Review 1.  Palliative Care for Parkinson's Spectrum Disorders: an Emerging Approach.

Authors:  Maya Katz
Journal:  Neurotherapeutics       Date:  2021-01-13       Impact factor: 7.620

2.  Development and validation of prognostic survival models in newly diagnosed Parkinson's disease.

Authors:  Angus D Macleod; Ingvild Dalen; Ole-Bjørn Tysnes; Jan Petter Larsen; Carl E Counsell
Journal:  Mov Disord       Date:  2017-10-04       Impact factor: 10.338

3.  A randomised controlled trial on effectiveness and feasibility of sport climbing in Parkinson's disease.

Authors:  Agnes Langer; Sebastian Hasenauer; Anna Flotz; Lucia Gassner; Rochus Pokan; Peter Dabnichki; Laurenz Wizany; Jakob Gruber; Dominik Roth; Sarah Zimmel; Marco Treven; Michaela Schmoeger; Ulrike Willinger; Walter Maetzler; Heidemarie Zach
Journal:  NPJ Parkinsons Dis       Date:  2021-06-10

4.  Reliability of Three Disability Scales for Detection of Independence Loss in Parkinson's Disease.

Authors:  Anders Bjornestad; Ole-Bjorn Tysnes; Jan Petter Larsen; Guido Alves
Journal:  Parkinsons Dis       Date:  2016-04-24

5.  Co-morbidity burden in Parkinson's disease: Comparison with controls and its influence on prognosis.

Authors:  Angus D Macleod; Hannah Goddard; Carl E Counsell
Journal:  Parkinsonism Relat Disord       Date:  2016-05-14       Impact factor: 4.891

6.  Predictors of functional dependency in Parkinson's disease.

Authors:  Angus D Macleod; Carl E Counsell
Journal:  Mov Disord       Date:  2016-10       Impact factor: 10.338

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.